Tenax Therapeutics (TENX) Change in Receivables (2022 - 2025)
Tenax Therapeutics (TENX) posted quarterly Change in Receivables of -$1.2 million for Q1 2025, down 6900.0% year-over-year from $18000.0 in Q1 2024, and down 439.37% on a QoQ basis from $360670.0 in Q4 2024.
Tenax Therapeutics (TENX) Change in Receivables (2022 - 2025) Analysis & Trends
Tenax Therapeutics has reported Change in Receivables for 4 years, with the latest figure at -$1.2 million in Q1 2025.
- Change in Receivables for Q1 2025 came in at -$1.2 million, down 6900.0% year-over-year; the trailing twelve-month figure through Mar 2025 was -$1.3 million (down 332.64% YoY), and the FY2024 annual result was -$58000.0, down 118.95% from the prior year.
- Change in Receivables fell to -$1.2 million in Q1 2025, from $360670.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $963079.0 in Q4 2022 and troughed at -$1.4 million in Q3 2022.
- A 4-year average of -$126439.5 and a median of -$36834.0 in 2023 frame the typical range for Change in Receivables.
- The widest annual swing landed in 2024, when Change in Receivables soared 1079.18%; it then plunged 6900.0% in 2025.
- A 4-year view of Change in Receivables shows it stood at $963079.0 in 2022, then slumped by 103.82% to -$36834.0 in 2023, then soared by 1079.18% to $360670.0 in 2024, then tumbled by 439.37% to -$1.2 million in 2025.
- Per Business Quant data, the three most recent Change in Receivables figures were -$1.2 million in Q1 2025, $360670.0 in Q4 2024, and $240931.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -1.22 Mn |
| Mar 31, 2025 | -1.22 Mn |
| Dec 31, 2024 | 360,670.00 |
| Dec 31, 2024 | 360,670.00 |
| Sep 30, 2024 | 240,931.00 |
| Sep 30, 2024 | 240,931.00 |
| Jun 30, 2024 | -677,601.00 |
| Jun 30, 2024 | -677,601.00 |
| Mar 31, 2024 | 18,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Dec 31, 2023 | -36,834.00 |
| Dec 31, 2023 | -36,834.00 |
| Sep 30, 2023 | 782,483.00 |
| Sep 30, 2023 | 782,483.00 |
| Jun 30, 2023 | -204,847.00 |
| Jun 30, 2023 | -204,847.00 |
| Mar 31, 2023 | -234,802.00 |
| Mar 31, 2023 | -234,802.00 |
| Dec 31, 2022 | 963,079.00 |
| Dec 31, 2022 | 963,079.00 |